Top pharmacovigilance trend in 2017
The Expanding role of pharmacovigilance in rapidly changing regulatory and commercial climates.
An important new industry study from ProductLife Group highlights the ways good-pharmacovigilance-practice (GVP) guidelines, increased globalisation, and heightened business demands have propelled pharmacovigilance up the life sciences agenda and expanded the demands and challenges regulatory teams face.
Implications for safety and quality assurance extend far beyond the boundaries of regulatory affairs by requiring advance cooperation and data sharing between a range of operational functions. A further trend is an emphasis on risk–benefit balance: companies are now expected to consider the benefits of a product in terms of what it means to patients.
Intensifying commercial pressures also have a bearing on the role of pharmacovigilance to the extent that a new type of pharmacovigilance professional is now emerging — one who blends expertise in safety and quality with a rounded understanding of global regulations and requirements as well as business and budget management expertise.
The study highlights
• The effect GVP guidelines are having on the role of pharmacovigilance and its relationship with quality
• The role safety must play in the decision-making process
• Skills gaps and recruitment implications
• Global complexities, including different regions’ changing GVP requirements and the implications for affiliates.
Drawing on the findings, captured through in-depth interviews with key life sciences industry figures, PLG Evolve—ProductLife Group’s thought leadership programme—will present a Webinar detailing the top pharmacovigilance trends for 2017, the effects they’ll have on the expanding role of pharmacovigilance, and the challenges faced by those involved.
Speakers
• Guest presenter Lesley Wise, PhD, is managing director of Wise Pharmacovigilance and Risk Management, a consultant to companies, contract research organisations, and independent research groups. She has more than 15 years of experience in pharmacovigilance both in medicines regulation as head of the risk management and pharmacoepidemiology group at the Medicines and Healthcare products Regulatory Agency and in the pharmaceutical industry, most recently at Takeda Pharmaceuticals. Lesley has a doctorate in statistical genetics/genetic epidemiology. She is an honorary lecturer in pharmacoepidemiology at the London School of Hygiene & Tropical Medicine and an associate editor of Therapeutic Advances in Drug Safety.
• Erick Gaussens, PhD, is chief scientific officer at ProductLife Group. He has deep knowledge of risk management and regulatory requirements in the life sciences industry and brings immeasurable expertise in cognitive science. His extensive R&D experience across several innovative and highly regulated industries gives him unique insight into the impacts of new regulations, new technologies, and the evolution of product life cycle management from both information management and business process perspectives. Erick’s doctorate in mathematics and Docteur d’État are from Université Paris-Dauphine.
• Cheryl Key, MBBS, is head of pharmacovigilance platform services and principal PV medic at ProductLife Group. She has gained more than 16 years of drug safety experience by working at pharmaceutical and biotech companies, for contract research organisations, and for regulatory authorities. Before joining what is now the Medicines and Healthcare products Regulatory Agency, Cheryl spent several years in medical practice. She has a medical degree from Charing Cross and Westminster Medical School.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance